PUBLISHER: The Insight Partners | PRODUCT CODE: 1567860
PUBLISHER: The Insight Partners | PRODUCT CODE: 1567860
The North America upstream bioprocessing market was valued at US$ 3,958.62 million in 2022 and is expected to reach US$ 10,603.38 million by 2030; it is estimated to grow at a CAGR of 13.1% from 2022 to 2030.
Commercial Use of Single-Use Bioreactors Fuels North America Upstream Bioprocessing Market.
Various manufacturers are developing single-use bioreactors (SUBs) due to their robust build and high performance, which are necessary for the commercial manufacturing of biopharmaceuticals. The incorporation of technologies associated with biofilm formation, stirring mechanisms, bioreactor designs, and sensor systems, among others, have resulted in the increased adoption of disposable reactors at the laboratory and production scales. Single-use bioreactors are operated to manufacture next-generation cell and gene therapies, and they are suitable for continuous bioprocessing. Advancements in cell-culture processes have developed higher titers and cell densities, facilitating the adoption of SUBs. Single-use bioreactors operate with a low risk of contamination, shorter production turnaround times, and reduced validation time. In the last few years, the use of single-use bioreactors has increased in modern biopharmaceutical processes owing to their unique ability to aid enhanced flexibility, reduce investments, and limit operational costs. Also, many companies have developed single-use bioreactors for producing a wide range of therapeutics. In March 2021, Thermo Fischer Scientific launched the 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors. Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10-15 mL micro bioreactor scale and Biostat STR for 50-2000L. The use of single-use bioreactors is subsequently increasing in upstream bioprocessing. Thus, the increasing acceptance of single-use bioreactors for the production of therapeutics propels the upstream bioprocessing market.
North America Upstream Bioprocessing Market Overview
The upstream bioprocessing market in North America is segmented into the US, Canada, and Mexico. Market growth in North America is attributed to the increasing demand for bioreactor systems from biopharmaceutical and biotechnology companies, the prominent presence of market players, and growing R&D efforts by academic and research institutes. In addition, research activities by pharmaceutical and biotechnology companies propel the upstream bioprocessing market growth in North America.
North America Upstream Bioprocessing Market Revenue and Forecast to 2030 (US$ Million)
North America Upstream Bioprocessing Market Segmentation
The North America upstream bioprocessing market is segmented based on product type, workflow, usage type, mode, and country.
Based on product type, the North America upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters services held the largest market share in 2022.
Based on workflow, the North America upstream bioprocessing market is categorized into media preparation, cell culture, and cell separation. The cell separation held the largest market share in 2022.
In terms of usage type, the North America upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use held a larger market share in 2022
By mode, the North America upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house held a larger market share in 2022.
Based on country, the North America upstream bioprocessing market is segmented into the US, Canada, and Mexico. The US dominated the North America upstream bioprocessing market share in 2022.
Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, Entegris Inc, and PBS Biotech Inc are some of the leading companies operating in the North America upstream bioprocessing market.